These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22161573)

  • 1. Particles in therapeutic protein formulations, Part 1: overview of analytical methods.
    Zölls S; Tantipolphan R; Wiggenhorn M; Winter G; Jiskoot W; Friess W; Hawe A
    J Pharm Sci; 2012 Mar; 101(3):914-35. PubMed ID: 22161573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of flow cytometry for the detection of subvisible particles in therapeutic protein formulations.
    Mach H; Bhambhani A; Meyer BK; Burek S; Davis H; Blue JT; Evans RK
    J Pharm Sci; 2011 May; 100(5):1671-8. PubMed ID: 21374606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Label-free flow cytometry analysis of subvisible aggregates in liquid IgG1 antibody formulations.
    Nishi H; Mathäs R; Fürst R; Winter G
    J Pharm Sci; 2014 Jan; 103(1):90-9. PubMed ID: 24218205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Nanoparticle Tracking Analysis for Quantification and Sizing of Submicron Particles of Therapeutic Proteins.
    Zhou C; Krueger AB; Barnard JG; Qi W; Carpenter JF
    J Pharm Sci; 2015 Aug; 104(8):2441-50. PubMed ID: 26017684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification and characterization of subvisible proteinaceous particles in opalescent mAb formulations using micro-flow imaging.
    Sharma DK; Oma P; Pollo MJ; Sukumar M
    J Pharm Sci; 2010 Jun; 99(6):2628-42. PubMed ID: 20049937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subvisible (2-100 μm) Particle Analysis During Biotherapeutic Drug Product Development: Part 1, Considerations and Strategy.
    Narhi LO; Corvari V; Ripple DC; Afonina N; Cecchini I; Defelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Spitznagel TM; Weiskopf A; Wuchner K
    J Pharm Sci; 2015 Jun; 104(6):1899-1908. PubMed ID: 25832583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Subvisible Particles in Biopharmaceutical Formulations Using Raman Spectroscopy Provides Insight into Polysorbate 20 Degradation Pathway.
    Saggu M; Liu J; Patel A
    Pharm Res; 2015 Sep; 32(9):2877-88. PubMed ID: 25773722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comprehensive Evaluation of Nanoparticle Tracking Analysis (NanoSight) for Characterization of Proteinaceous Submicron Particles.
    Tian X; Nejadnik MR; Baunsgaard D; Henriksen A; Rischel C; Jiskoot W
    J Pharm Sci; 2016 Nov; 105(11):3366-3375. PubMed ID: 27663383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics.
    Singh SK; Afonina N; Awwad M; Bechtold-Peters K; Blue JT; Chou D; Cromwell M; Krause HJ; Mahler HC; Meyer BK; Narhi L; Nesta DP; Spitznagel T
    J Pharm Sci; 2010 Aug; 99(8):3302-21. PubMed ID: 20310025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of Stress-Induced Aggregate Size Distributions and Morphological Changes of a Bi-Specific Antibody Using Orthogonal Techniques.
    Hamrang Z; Hussain M; Tingey K; Tracka M; Casas-Finet JR; Uddin S; van der Walle CF; Pluen A
    J Pharm Sci; 2015 Aug; 104(8):2473-81. PubMed ID: 26053418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical lessons learned from selected therapeutic protein drug comparability studies.
    Federici M; Lubiniecki A; Manikwar P; Volkin DB
    Biologicals; 2013 May; 41(3):131-47. PubMed ID: 23146362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Free fatty acid particles in protein formulations, part 1: microspectroscopic identification.
    Cao X; Fesinmeyer RM; Pierini CJ; Siska CC; Litowski JR; Brych S; Wen ZQ; Kleemann GR
    J Pharm Sci; 2015 Feb; 104(2):433-46. PubMed ID: 25175016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification and characterization of micrometer and submicrometer subvisible particles in protein therapeutics by use of a suspended microchannel resonator.
    Patel AR; Lau D; Liu J
    Anal Chem; 2012 Aug; 84(15):6833-40. PubMed ID: 22794526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-linked silicone coating: a novel prefilled syringe technology that reduces subvisible particles and maintains compatibility with biologics.
    Depaz RA; Chevolleau T; Jouffray S; Narwal R; Dimitrova MN
    J Pharm Sci; 2014 May; 103(5):1384-93. PubMed ID: 24643773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of image-based particle size and shape characterization systems in the development of small molecule pharmaceuticals.
    Gamble JF; Tobyn M; Hamey R
    J Pharm Sci; 2015 May; 104(5):1563-74. PubMed ID: 25690940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
    Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K
    Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods.
    Werk T; Volkin DB; Mahler HC
    Eur J Pharm Sci; 2014 Mar; 53():95-108. PubMed ID: 24370624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Closing the Gap: Counting and Sizing of Particles Across Submicron Range by Flow Cytometry in Therapeutic Protein Products.
    Zhang L; Shi S; Antochshuk V
    J Pharm Sci; 2017 Nov; 106(11):3215-3221. PubMed ID: 28625725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation development of lyophilized, long-term stable siRNA/oligoaminoamide polyplexes.
    Kasper JC; Troiber C; Küchler S; Wagner E; Friess W
    Eur J Pharm Biopharm; 2013 Oct; 85(2):294-305. PubMed ID: 23747745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Protein-Like Reference Material for Semiquantitatively Monitoring Visible Proteinaceous Particles in Biopharmaceuticals.
    Telikepalli S; Gonzalez K; Dragulin-Otto S; Ripple D; Carrier M; Khan M
    PDA J Pharm Sci Technol; 2019; 73(5):418-432. PubMed ID: 31209163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.